Interactive

A Look Into The Pharmaceutical Supply Chain With Examples Of Vulnerabilities


After HeparinDrug manufacturers and distributors work together in a robust system to deliver high-quality products, but our pharmaceutical supply has become increasingly complex in recent years. Medicines originate in factories all over the world, moving into the American marketplace through supply chains that can involve numerous processing plants, manufacturers, suppliers, brokers, packagers and distributors.

This interactive graphic presents and overview of today's globalized pharmaceutical supply chain and examines vulnerabilities that have allowed substandard and counterfeit products to enter the system.

Get Adobe Flash player

More Resources:

Date added:
Jan 10, 2012

Related Resources

Pew Testimony Before the U.S.-China Economic and Security Review Commission

Other Resource

Allan Coukell, senior director of drugs and medical devices, testified before the U.S.-China Economic and Security Review Commission on the global pharmaceutical supply chain security and the importance of the newly passed Drug Quality and Security Act.

More

Testimony of Elizabeth Jungman on Counterfeit Medicines

Issue Brief

The House Energy and Commerce Subcommittee on Oversight and Investigation held a hearing on Feb 16 entitled "Counterfeit Drugs: Fighting Illegal Supply Chains." Elizabeth Jungman, director of drug safety and innovation testified on counterfeit drugs the importance that newly passed Drug Quality and Security Act will have on the safety of the U.S. pharmaceutical supply chain.

 

More

Case Studies: How Unsafe Drugs Can Reach Patients

Issue Brief

The following case studies illustrate breaches to the pharmaceutical supply chain—the route a drug travels from its raw material origins to the delivery of a finished medicine. These examples, all of which are discussed in Pew Health Group’s report After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs, demonstrate the different ways in which contaminated, fake, or otherwise unsafe medicine can reach patients, and underscore the need for reform.

More

Drug Distribution Security: Title II of the Drug Quality and Security Act

Other Resource

The landmark Drug Quality and Security Act was signed into law in late 2013 to address these risks and to create a new national framework for securing the drug distribution supply chain. Title II of the law, the Drug Supply Chain Security Act, establishes a national system to enable supply chain partners and regulators to trace back each package of a drug from the pharmacy where it is dispensed to the manufacturer.

More

Pharmaceutical Compounding: Title I of the Drug Quality and Security Act

Other Resource

On Nov. 27, 2013, President Barack Obama signed the landmark Drug Quality and Security Act, a new law designed to improve safety within the U.S. pharmaceutical supply by addressing these risks. Title I of the act contains important updates to oversight systems for pharmaceutical compounding. Compounding—the creation of customized medicines to meet patients’ unique needs—is traditionally practiced by pharmacies and regulated by state authorities. Over the years, this activity has expanded to include companies that compound medicine on a large scale but do not undergo the same scrutiny given to pharmaceutical manufacturers.

More

Pew Comments to FDA Draft Guidance on 503A

Issue Brief

On January 31, Pew submitted comments to the U.S. Food and Drug Administration in response to draft guidance on the implementation of Title I of the Drug Quality and Security Act and addressed five topics: anticipatory and office stock compounding; quality standards; FDA / state coordination; MOUs to address inordinate interstate shipment of compounded drugs; use of bulk drug substances.

More

FDA Releases Compounding Guidance

Other Resource

On Nov. 27, President Barack Obama signed the landmark Drug Quality and Security Act, a law that aims to improve the safety of the U.S. pharmaceutical supply. Title I of the act contains important updates to oversight systems for pharmaceutical compounding, and on Dec. 3, the U.S. Food and Drug Administration, or FDA, released for public comment six guidance and regulatory documents for implementing the new law.

More

Reuters: U.S. Compounding Pharmacies Start to Register With FDA

Media Coverage

A small number of U.S. compounding pharmacies have begun registering with the Food and Drug Administration under new legislation designed to tighten control of the custom medication makers following a deadly outbreak of fungal meningitis linked to a pharmacy in Massachusetts.

More

Improving the Safety and Quality of Our Drug Supply

Other Resource
On Nov. 18, 2013, Congress passed the landmark Drug Quality and Security Act, bipartisan legislation to safeguard the U.S. pharmaceutical supply from counterfeit and contaminated drugs. The act creates a national system to track and authenticate prescription medications as they progress from the manufacturer to the patient. It also addresses the risks posed by drugs made by large-scale compounding pharmacies. More

Reuters: U.S. Senate Backs Bill to Regulate Bulk Drug Compounding

Media Coverage
The U.S. Senate on Monday approved a bill designed to prevent the type of quality control problems that led last year to a deadly outbreak of fungal meningitis traced to a tainted pharmaceutical mixed by a Massachusetts pharmacy. More

Pew Hails Passage of Drug Quality and Security Act, a Step Forward for Drug and Patient Safety

Press Release

In response to final Senate passage of the Drug Quality and Security Act—legislation that establishes a national standard for tracing pharmaceuticals through the drug supply system and clarifies federal authority over pharmaceutical compounding—Allan Coukell, senior director of drugs and medical devices at The Pew Charitable Trusts, issued the following statement.

More

New York Times: Bill on Drug Compounding Clears Congress a Year After a Meningitis Outbreak

Media Coverage
A bill that would give the Food and Drug Administration more power to police compounding pharmacies passed its final hurdle in Congress on Monday, in what experts said was an important step to a safer drug supply in the United States. More

Associated Press: Pharmacy Bill Set for Test Vote in Senate

Media Coverage

A year after a meningitis outbreak from contaminated pain injections killed at least 64 people and sickened hundreds, Congress is ready to increase federal oversight over compounding pharmacies that custom-mix medications.

More

Minneapolis Star-Tribune: U.S. Senate Must Act on Pharmacy Safeguards

Opinion

It's been more than a year since a deadly fungal meningitis outbreak traced to a filthy New England compounding pharmacy put a shocking spotlight on the risks of medications mass-produced by underregulated firms.

More

Letter from Pew and The Pharmaceutical Distribution Security Alliance to Senate Leadership Calling for Passage of Track and Trace Legislation

Other Resource

Pew and the Pharmaceutical Distribution Security Alliance, or PDSA, PDSA have co-signed a letter asking Majority Leader Harry Reid (D-NV) and Republican Leader Mitch McConnell (R-KY) to pass The Drug Quality and Security Act (HR 3204), which would implement a “track and trace” system for the U.S. pharmaceutical distribution supply chain and enhanced federal oversight of compounding pharmacies to safeguard the nation’s drug supply against counterfeit and contaminated medicines.

More